Preclinical therapeutics for sickle cell disease: modern developments and future considerations [0.03%]
镰状细胞病的临床前治疗：现代进展与未来展望
Iheanyi Okpala,Charles Nonyelu,Ebele Muoghalu et al.
Iheanyi Okpala et al.
Introduction: Most of the current treatment modalities for sickle hemoglobinopathy are disease-modifying rather than curative. Therefore, there is need for effective treatment of complications of sickle cell disease (SCD)...
Chronic lymphocytic leukemia: what clinical progress have we seen in the last five years? [0.03%]
慢性淋巴细胞白血病：过去五年中我们取得了哪些临床进展？
Elżbieta Iskierka-Jażdżewska,Bartosz Puła,Krzysztof Jamroziak et al.
Elżbieta Iskierka-Jażdżewska et al.
Introduction: Chronic lymphocytic leukemia (CLL) is the most common form of leukemia in adults. Although treatment has shifted from immunochemotherapy to novel targeted drugs over the last 10 years, novel therapies remain...
Endothelin receptor antagonists for diabetic kidney disease: back to the future? [0.03%]
糖尿病肾病的内皮素受体拮抗剂治疗：回溯未来？
Panagiota Anyfanti,Marieta Theodorakopoulou,Fotini Iatridi et al.
Panagiota Anyfanti et al.
Introduction: Diabetic kidney disease (DKD) is a leading cause of chronic kidney disease worldwide. Endothelin-1 (ET-1) is a potent vasoconstrictor secreted by vascular endothelial cells, actively involved in the pathophy...
The bispecific antibody AZD0486: an overview of the clinical journey to date with a focus on follicular lymphoma [0.03%]
AZD0486双特异性抗体的临床历程概述及其在滤泡性淋巴瘤中的应用:focus on follicular lymphoma）
Harry Hambleton,Chan Y Cheah
Harry Hambleton
Introduction: Follicular Lymphoma (FL) is the most common indolent lymphoma. Patients with advanced stage FL typically respond to therapy, then follow a relapsing/remitting course, with shorter progression-free survival w...
Safety, tolerability, pharmacokinetics, and pharmacodynamics of SHR-2010, a novel anti-MASP-2 antibody, in healthy volunteers: a randomized, double-blind, placebo-controlled phase 1 study [0.03%]
SHR-2010新型抗MASP-2抗体在健康志愿者中的安全性、耐受性、药代动力学和药效学：随机、双盲、安慰剂对照Ⅰ期临床试验
Pingping Lin,Chenjing Wang,Xiaotong Hu et al.
Pingping Lin et al.
Background: This first-in-human study assessed the safety, tolerability, pharmacokinetics, and pharmacodynamics of SHR-2010, a novel humanized IgG4 monoclonal antibody targeting mannan-binding lectin serine protease-2, in...
Sunil Dogra,Sukhdeep Singh
Sunil Dogra
Introduction-: Sonelokimab, a bispecific nanobody targeting interleukins (IL)-17A and IL-17F, has emerged as a novel therapeutic candidate for chronic inflammatory diseases such as psoriasis, hidradenitis suppurativa (HS)...
Anushka Bhatt,Pramiti Gupta,Richard Furie et al.
Anushka Bhatt et al.
Introduction: Patients with Systemic Lupus Erythematosus (SLE) experience varied manifestations and unpredictable flares, complicating treatment and drug development. Despite these challenges, anifrolumab, voclosporin, an...
The promise of glucagon-like peptide 1 receptor agonists (GLP-1RA) for the treatment of obesity: a look at phase 2 and 3 pipelines [0.03%]
胰高血糖素样肽1受体激动剂(GLP-1RA)治疗肥胖的前景：对二期和三期管线的分析
Sten Madsbad,Jens J Holst
Sten Madsbad
Introduction: GLP-1-based therapies have changed the treatment of overweight/obesity. Liraglutide 3.0 mg daily, the first GLP-1 RA approved for treatment of overweight, induced a weight loss of 6-8%, Semaglutide 2.4 mg on...
Tucatinib in the treatment of HER2-overexpressing gastrointestinal cancers: current insights and future prospects [0.03%]
Tucatinib 在治疗 HER2 过表达的胃肠癌中的应用：当前认识和未来展望
Celine Hoyek,Binbin Zheng-Lin,Jeremy Jones et al.
Celine Hoyek et al.
Introduction: Over the past 20 years, the treatment landscape of HER2-amplified tumors has considerably evolved. Until recently, no approved targeted therapies were available to patients with HER2-amplified metastatic col...
The pleiotropic effects of glucagon-like peptide-1 receptor agonists in patients with metabolic dysfunction-associated steatohepatitis: a review for gastroenterologists [0.03%]
胰高血糖素样肽-1受体激动剂在与代谢功能障碍相关性脂肪肝患者中的多效作用：一项针对胃肠病学者的综述
Naim Alkhouri,Michael Charlton,Meagan Gray et al.
Naim Alkhouri et al.
Introduction: Glucagon-like peptide-1 receptor agonists (GLP-1RAs), and dual GLP-1/glucose-dependent insulinotropic peptide (GIP) or glucagon receptor agonists have emerged as promising agents to treat metabolic dysfuncti...